NNNN
Anbio Biotechnology Ltd
NASDAQ · Biotechnology
$25.65
+1.59 (+6.61%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 8.27M | 6.74M | 1.91B | 1.84B | 1.79B |
| Net Income | 2.40M | 1.76M | -342,978,964 | -354,337,532 | -367,227,211 |
| EPS | — | — | — | — | — |
| Profit Margin | 29.0% | 27.5% | -18.0% | -19.2% | -20.5% |
| Rev Growth | +22.7% | +22.7% | +20.7% | +17.6% | +11.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 773.91M | 886.33M | 752.45M |
| Total Equity | — | — | 2.02B | 1.73B | 1.94B |
| D/E Ratio | — | — | 0.38 | 0.51 | 0.39 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 2.04M | 1.58M | -481,091,076 | -454,323,212 | -381,836,603 |
| Free Cash Flow | — | — | -336,718,909 | -249,462,362 | -276,575,086 |